Annual Drug Patent Expirations for TRIUMEQ
Triumeq is a drug marketed by Viiv Hlthcare and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for TRIUMEQ.
This drug has one hundred and twenty-four patent family members in thirty-three countries.
The generic ingredient in TRIUMEQ is abacavir sulfate; dolutegravir sodium; lamivudine. One supplier is listed for this compound. Additional details are available on the abacavir sulfate; dolutegravir sodium; lamivudine profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
